JP3370324B2 - ヒトインターロイキン−６受容体に対する再構成ヒト抗体 - Google Patents
ヒトインターロイキン−６受容体に対する再構成ヒト抗体Info
- Publication number
- JP3370324B2 JP3370324B2 JP50889892A JP50889892A JP3370324B2 JP 3370324 B2 JP3370324 B2 JP 3370324B2 JP 50889892 A JP50889892 A JP 50889892A JP 50889892 A JP50889892 A JP 50889892A JP 3370324 B2 JP3370324 B2 JP 3370324B2
- Authority
- JP
- Japan
- Prior art keywords
- chain
- region
- human
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 521
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 title claims abstract description 9
- 102000052623 human IL6R Human genes 0.000 title claims abstract description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 76
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims abstract description 41
- 150000001413 amino acids Chemical class 0.000 claims description 89
- 239000013598 vector Substances 0.000 claims description 80
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 61
- 230000027455 binding Effects 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 108090001005 Interleukin-6 Proteins 0.000 claims description 25
- 102000004889 Interleukin-6 Human genes 0.000 claims description 24
- 229940100601 interleukin-6 Drugs 0.000 claims description 24
- 102000005962 receptors Human genes 0.000 claims description 24
- 108020003175 receptors Proteins 0.000 claims description 24
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 22
- 102000052611 human IL6 Human genes 0.000 claims description 20
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 2
- 229940116886 human interleukin-6 Drugs 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 230000000890 antigenic effect Effects 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 abstract 3
- 108010038501 Interleukin-6 Receptors Proteins 0.000 abstract 3
- 108020004414 DNA Proteins 0.000 description 193
- 238000003752 polymerase chain reaction Methods 0.000 description 175
- 241000699666 Mus <mouse, genus> Species 0.000 description 160
- 108091028043 Nucleic acid sequence Proteins 0.000 description 120
- 210000004027 cell Anatomy 0.000 description 113
- 150000007523 nucleic acids Chemical group 0.000 description 98
- 238000006243 chemical reaction Methods 0.000 description 92
- 235000001014 amino acid Nutrition 0.000 description 81
- 229940024606 amino acid Drugs 0.000 description 80
- 239000012634 fragment Substances 0.000 description 69
- 108090000623 proteins and genes Proteins 0.000 description 67
- 239000000047 product Substances 0.000 description 66
- 239000013604 expression vector Substances 0.000 description 61
- 108020004707 nucleic acids Proteins 0.000 description 49
- 102000039446 nucleic acids Human genes 0.000 description 49
- 239000013612 plasmid Substances 0.000 description 49
- 230000014509 gene expression Effects 0.000 description 46
- 239000002773 nucleotide Substances 0.000 description 33
- 125000003729 nucleotide group Chemical group 0.000 description 33
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 28
- 239000002299 complementary DNA Substances 0.000 description 26
- 238000005406 washing Methods 0.000 description 26
- 239000003623 enhancer Substances 0.000 description 25
- 210000004408 hybridoma Anatomy 0.000 description 25
- 238000002965 ELISA Methods 0.000 description 24
- 239000000427 antigen Substances 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 238000013461 design Methods 0.000 description 20
- 238000011534 incubation Methods 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 238000002844 melting Methods 0.000 description 17
- 230000008018 melting Effects 0.000 description 17
- 101150074155 DHFR gene Proteins 0.000 description 16
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 15
- 230000003321 amplification Effects 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 239000011543 agarose gel Substances 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 239000012228 culture supernatant Substances 0.000 description 13
- 238000002703 mutagenesis Methods 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 231100000350 mutagenesis Toxicity 0.000 description 11
- 231100000219 mutagenic Toxicity 0.000 description 11
- 230000003505 mutagenic effect Effects 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 10
- 241000283707 Capra Species 0.000 description 10
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 210000004962 mammalian cell Anatomy 0.000 description 10
- 201000000050 myeloid neoplasm Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 229920000936 Agarose Polymers 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000010474 transient expression Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 5
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001024304 Mino Species 0.000 description 3
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 3
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- XKJMBINCVNINCA-UHFFFAOYSA-N Alfalone Chemical compound CON(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XKJMBINCVNINCA-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100452395 Mus musculus Il6ra gene Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 102220201851 rs143406017 Human genes 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- KVHHQGIIZCJATJ-UHFFFAOYSA-N 1-(4-chlorophenyl)-4-(dimethylamino)-2,3-dimethyl-2-butanol Chemical compound CN(C)CC(C)C(C)(O)CC1=CC=C(Cl)C=C1 KVHHQGIIZCJATJ-UHFFFAOYSA-N 0.000 description 1
- 101150046224 ABAT gene Proteins 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 1
- 101100297421 Homarus americanus phc-2 gene Proteins 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000408495 Iton Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100065514 Mus musculus Eral1 gene Proteins 0.000 description 1
- 101001091370 Mus musculus Kallikrein-8 Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150102573 PCR1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- -1 guanidine thiol Chemical class 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000004 low energy electron diffraction Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010024226 placental ribonuclease inhibitor Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3-95476 | 1991-04-25 | ||
| JP3095476A JPH05236966A (ja) | 1991-04-25 | 1991-04-25 | ヒトインターロイキン−６レセプターに対するマウスモノクローナル抗体の可変領域をコードするｄｎａ |
| JP4-32084 | 1992-02-19 | ||
| JP4032084A JPH05227970A (ja) | 1992-02-19 | 1992-02-19 | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| PCT/JP1992/000544 WO1992019759A1 (fr) | 1991-04-25 | 1992-04-24 | Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP33828699A Division JP3176598B2 (ja) | 1991-04-25 | 1999-11-29 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO1992019759A1 JPWO1992019759A1 (ja) | 1993-05-13 |
| JP3370324B2 true JP3370324B2 (ja) | 2003-01-27 |
Family
ID=26370596
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50889892A Expired - Lifetime JP3370324B2 (ja) | 1991-04-25 | 1992-04-24 | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| JP33828699A Expired - Lifetime JP3176598B2 (ja) | 1991-04-25 | 1999-11-29 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
| JP2000229748A Expired - Lifetime JP3913965B2 (ja) | 1991-04-25 | 2000-07-28 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
| JP2003347675A Expired - Lifetime JP3616087B2 (ja) | 1991-04-25 | 2003-10-06 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
| JP2006338832A Withdrawn JP2007082560A (ja) | 1991-04-25 | 2006-12-15 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
| JP2007255248A Pending JP2008073049A (ja) | 1991-04-25 | 2007-09-28 | ヒトインターロイキン−６受容体に対する抗体を産生するハイブリドーマ |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP33828699A Expired - Lifetime JP3176598B2 (ja) | 1991-04-25 | 1999-11-29 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
| JP2000229748A Expired - Lifetime JP3913965B2 (ja) | 1991-04-25 | 2000-07-28 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
| JP2003347675A Expired - Lifetime JP3616087B2 (ja) | 1991-04-25 | 2003-10-06 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
| JP2006338832A Withdrawn JP2007082560A (ja) | 1991-04-25 | 2006-12-15 | ヒトインターロイキン−６受容体に対するキメラ抗体 |
| JP2007255248A Pending JP2008073049A (ja) | 1991-04-25 | 2007-09-28 | ヒトインターロイキン−６受容体に対する抗体を産生するハイブリドーマ |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US5795965A (member.php) |
| EP (1) | EP0628639B1 (member.php) |
| JP (6) | JP3370324B2 (member.php) |
| KR (1) | KR100249937B1 (member.php) |
| AT (1) | ATE181575T1 (member.php) |
| AU (2) | AU668349B2 (member.php) |
| DE (2) | DE69229482T2 (member.php) |
| DK (1) | DK0628639T3 (member.php) |
| ES (1) | ES2134212T3 (member.php) |
| GR (1) | GR3031174T3 (member.php) |
| HU (1) | HU218140B (member.php) |
| LU (1) | LU91556I2 (member.php) |
| NL (1) | NL300383I2 (member.php) |
| RU (1) | RU2139351C1 (member.php) |
| TW (1) | TW205553B (member.php) |
| WO (1) | WO1992019759A1 (member.php) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021211006A1 (en) | 2020-04-13 | 2021-10-21 | Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency | Inhaled hexapeptide for treating interleukin-6 related respiratory diseases |
| WO2022005321A1 (en) | 2020-06-29 | 2022-01-06 | Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency | Inhaled tocilizumab for treating interleukin-6 related respiratory diseases |
Families Citing this family (336)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5472693A (en) * | 1993-02-16 | 1995-12-05 | The Dow Chemical Company | Family of anti-carcinoembryonic antigen chimeric antibodies |
| WO1994028159A1 (en) * | 1993-05-31 | 1994-12-08 | Chugai Seiyaku Kabushiki Kaisha | Reconstructed human antibody against human interleukin-6 |
| DE69332911T2 (de) * | 1993-08-24 | 2003-12-18 | Nissin Shokuhin K.K., Osaka | Rekombinanter humanisierter Antikörper gegen menschlichen Immunschwächevirus |
| US5914110A (en) * | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| AU7949394A (en) * | 1993-11-19 | 1995-06-06 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
| WO1995029690A1 (en) * | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Biologically active peptides and methods of identifying the same |
| US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| CA2201781C (en) * | 1994-10-07 | 2010-01-12 | Tadamitsu Kishimoto | Chronic rheumatoid arthritis therapy containing il-6 antagonist as effective component |
| EP1884524A3 (en) * | 1994-10-21 | 2008-06-25 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment of diseases caused by IL-6 production |
| ATE330629T1 (de) * | 1995-02-13 | 2006-07-15 | Chugai Pharmaceutical Co Ltd | Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper |
| ATE326238T1 (de) | 1996-06-27 | 2006-06-15 | Chugai Pharmaceutical Co Ltd | Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann |
| BR9713294A (pt) | 1996-09-26 | 2000-10-17 | Chugai Pharmaceutical Co Ltd | "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano" |
| UA76934C2 (en) | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
| RU2177805C2 (ru) * | 1997-02-12 | 2002-01-10 | Чугаи Сейяку Кабусики Кайся | Средство, применяемое при лечении опухолей лимфатической ткани |
| ES2312184T3 (es) | 1997-03-21 | 2009-02-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas. |
| TR199902800T2 (xx) | 1997-05-15 | 2000-04-21 | Chugai Seiyaku Kabushiki Kaisha | Ka�eksiyi tedavi edici madde. |
| DK1004315T3 (da) * | 1997-08-15 | 2008-07-21 | Chugai Pharmaceutical Co Ltd | Forebyggende midler og/eller lægemidler indeholdende anti-IL6-receptorneutraliserende antistoffer til reduktion af urinproteinudskillelsen ved systemisk lupus erythematosus |
| US20020187150A1 (en) * | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| DE69937994T2 (de) | 1998-03-17 | 2008-12-24 | Chugai Seiyaku K.K. | Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper |
| SK14812000A3 (sk) | 1998-04-03 | 2001-08-06 | Chugai Seiyaku Kabushiki Kaisha | Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo |
| EP1108435B1 (en) * | 1998-08-24 | 2007-01-03 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for pancreatitis containing anti-il-6 receptor antibodies as the active ingredient |
| EP1721979B1 (en) | 1998-11-27 | 2010-09-15 | Ucb, S.A. | Compositions and methods for increasing bone mineralisation |
| US7696325B2 (en) | 1999-03-10 | 2010-04-13 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide inducing apoptosis |
| AU7078200A (en) * | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use |
| HUP0203486A2 (hu) | 1999-10-01 | 2003-02-28 | Chugai Seiyaku Kabushiki Kaisha | Véralvadással összefüggő betegségek megelőzése és kezelése |
| GB0002666D0 (en) | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
| WO2001082968A1 (fr) | 2000-04-28 | 2001-11-08 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs de proliferation cellulaire |
| PT1314437E (pt) | 2000-08-11 | 2014-08-29 | Chugai Pharmaceutical Co Ltd | Preparações estabilizadas contendo anticorpo |
| WO2002032374A2 (en) * | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| ES2304235T3 (es) | 2000-10-20 | 2008-10-01 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo agonista de tpo modificado. |
| AU1091802A (en) | 2000-10-20 | 2002-04-29 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibody |
| JP4261907B2 (ja) | 2000-10-20 | 2009-05-13 | 中外製薬株式会社 | 低分子化アゴニスト抗体 |
| AU2002210952B2 (en) | 2000-10-25 | 2007-01-11 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist |
| AU2000279624A1 (en) * | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient |
| AU2000279625A1 (en) * | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
| JP3986439B2 (ja) | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | 造血器腫瘍の治療剤 |
| US20030044406A1 (en) * | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| EP2336149A1 (en) | 2001-03-09 | 2011-06-22 | Chugai Seiyaku Kabushiki Kaisha | Protein purification method |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| WO2002086492A1 (en) | 2001-04-17 | 2002-10-31 | Chugai Seiyaku Kabushiki Kaisha | Method of quantifying surfactant |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| CA2447139C (en) | 2001-05-11 | 2013-11-19 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| WO2003068259A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| GB0208041D0 (en) * | 2002-04-08 | 2002-05-22 | Lonza Biologics Plc | Method of culturing animal cells |
| AU2003235948A1 (en) * | 2002-04-25 | 2003-11-10 | Chugai Seiyaku Kabushiki Kaisha | Remedy for lung cancer |
| NZ556507A (en) * | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
| WO2004019966A1 (ja) | 2002-08-27 | 2004-03-11 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液製剤の安定化方法 |
| AU2002338020A1 (en) | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
| DK2261230T3 (en) | 2002-09-11 | 2017-06-12 | Chugai Pharmaceutical Co Ltd | Method of Protein Purification. |
| CN100340294C (zh) * | 2003-02-24 | 2007-10-03 | 中外制药株式会社 | 含有白介素6拮抗剂的脊髓损伤治疗剂 |
| JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| NO345763B1 (no) | 2003-06-16 | 2021-07-19 | Celltech R&D Inc | Immunogen og antistoffer spesifikke for sklerostin, samt farmasøytiske preparater for å øke benmineralisering. |
| TW200510532A (en) | 2003-07-15 | 2005-03-16 | Chugai Pharmaceutical Co Ltd | IgM production by transformed cell and method of quantifying the same |
| ES2392824T3 (es) | 2003-10-17 | 2012-12-14 | Chugai Seiyaku Kabushiki Kaisha | Agente terapéutico contra el mesotelioma |
| CA2548185A1 (en) | 2003-12-03 | 2005-06-16 | Chugai Seiyaku Kabushiki Kaisha | Expression systems using mammalian .beta.-actin promoter |
| US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
| US20080145367A1 (en) * | 2004-02-11 | 2008-06-19 | Warner-Lambert Compay, Llc | Methods of Treating Osteoarthritis with Il-6 Antagonists |
| US20050288491A1 (en) * | 2004-02-17 | 2005-12-29 | Wilson David S | Super-humanized antibodies against respiratory syncytial virus |
| US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| AR048335A1 (es) * | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
| US8398980B2 (en) | 2004-03-24 | 2013-03-19 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleuken-6 receptor |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| GB0410627D0 (en) * | 2004-05-12 | 2004-06-16 | Scancell Ltd | Specific binding members |
| WO2006046661A1 (ja) * | 2004-10-28 | 2006-05-04 | Osaka University | インターロイキン－６阻害剤 |
| KR101573529B1 (ko) | 2005-01-05 | 2015-12-01 | 추가이 세이야쿠 가부시키가이샤 | 세포의 배양 방법 및 그 이용 |
| PL1859793T3 (pl) * | 2005-02-28 | 2011-09-30 | Eisai R&D Man Co Ltd | Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej |
| WO2006106903A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | sc(Fv)2構造異性体 |
| CA2603408C (en) | 2005-03-31 | 2018-08-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| KR101360671B1 (ko) | 2005-06-10 | 2014-02-07 | 추가이 세이야쿠 가부시키가이샤 | ｓｃ（Ｆｖ）２를 함유하는 의약조성물 |
| CA2610987C (en) | 2005-06-10 | 2013-09-10 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
| US9243062B2 (en) * | 2005-08-11 | 2016-01-26 | Arpi Matossian-Rogers | Peptides for treatment and diagnosis of autoimmune disease |
| WO2007043641A1 (ja) | 2005-10-14 | 2007-04-19 | Fukuoka University | 膵島移植における移植膵島障害抑制剤 |
| EP1941908B1 (en) | 2005-10-21 | 2015-08-19 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for heart disease |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| EP1964574B1 (en) | 2005-11-14 | 2016-09-07 | Cellmid Limited | Method for treatment or prevention of disease associated with functional disorder of regulatory t cell |
| AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
| KR20080084818A (ko) * | 2005-11-25 | 2008-09-19 | 각고호우징 게이오기주크 | 전립선암 치료제 |
| EP1977763A4 (en) | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
| JP5033643B2 (ja) | 2006-01-27 | 2012-09-26 | 学校法人慶應義塾 | 脈絡膜血管新生を伴う疾患の治療剤 |
| EP1997505A4 (en) | 2006-03-22 | 2013-02-13 | Chugai Pharmaceutical Co Ltd | PREPARATION OF ERYTHROPOIETIN SOLUTION |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| ES2654040T3 (es) | 2006-03-31 | 2018-02-12 | Chugai Seiyaku Kabushiki Kaisha | Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos |
| WO2007116962A1 (ja) | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
| US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
| EA017303B1 (ru) * | 2006-05-25 | 2012-11-30 | Глаксо Груп Лимитед | Модифицированные гуманизированные антитела против интерлейкина-18 и их применение |
| SI2374818T1 (sl) | 2006-06-02 | 2013-03-29 | Regeneron Pharmaceuticals, Inc. | Visokoafinitetna protitelesa za humani IL-6 receptor |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| JP2009539403A (ja) | 2006-06-13 | 2009-11-19 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌を診断および処置するための組成物および方法 |
| CN101573383B (zh) | 2006-06-21 | 2015-05-13 | 肿瘤疗法科学股份有限公司 | 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途 |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| US20080081041A1 (en) * | 2006-09-29 | 2008-04-03 | Jeffrey Nemeth | Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer |
| RU2450829C2 (ru) | 2007-01-23 | 2012-05-20 | Синсу Юниверсити | Ингибитор хронического отторжения |
| CA2676008A1 (en) | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| CN101711284A (zh) | 2007-01-25 | 2010-05-19 | 达娜-法勃肿瘤研究所 | 抗egfr抗体在治疗egfr突变体介导的疾病中的用途 |
| CL2008000719A1 (es) | 2007-03-12 | 2008-09-05 | Univ Tokushima Chugai Seiyaku | Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| CN101868477A (zh) * | 2007-05-21 | 2010-10-20 | 奥尔德生物制药公司 | 新型兔抗体人源化方法和人源化的兔抗体 |
| EP2164514B1 (en) * | 2007-05-21 | 2016-12-14 | AlderBio Holdings LLC | Antibodies to il-6 and use thereof |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| JP5142265B2 (ja) | 2007-05-28 | 2013-02-13 | 独立行政法人産業技術総合研究所 | 抗モータリン抗体のパラトープ及びエピトープ |
| US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
| EP2174667B1 (en) | 2007-07-26 | 2017-01-04 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
| EP2185693B1 (en) | 2007-07-31 | 2019-07-03 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
| CA2696360C (en) | 2007-08-14 | 2018-11-20 | Ludwig Institute For Cancer Research | Monoclonal antibody targeting the egfr receptor and uses thereof |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| CN101939425B (zh) | 2007-09-26 | 2014-05-14 | 中外制药株式会社 | 抗il-6受体抗体 |
| RU2526512C2 (ru) * | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| JP5264752B2 (ja) | 2007-10-02 | 2013-08-14 | 中外製薬株式会社 | インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤 |
| JP4976502B2 (ja) * | 2007-10-15 | 2012-07-18 | 中外製薬株式会社 | 抗体の製造方法 |
| MX2010005805A (es) | 2007-11-27 | 2010-06-09 | Lifescan Inc | Diferenciacion de celulas madre embrionarias humanas. |
| MY177564A (en) | 2007-12-05 | 2020-09-20 | Chugai Pharmaceutical Co Ltd | Anti-nr10 antibody and use thereof |
| WO2009075344A1 (ja) | 2007-12-12 | 2009-06-18 | Japan As Represented By Director General Of Agency Of National Cancer Center | M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用 |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| WO2009095489A2 (en) * | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| CN102046779A (zh) | 2008-02-21 | 2011-05-04 | 森托科尔奥索生物科技公司 | 用于细胞粘附、培养和分离的方法、表面改性培养板和组合物 |
| CA2721052C (en) * | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| US8623648B2 (en) | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
| EP2282769A4 (en) * | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| MX2010012031A (es) | 2008-05-13 | 2011-01-20 | Novimmune Sa | Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos. |
| KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| NZ589434A (en) | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2728243C (en) | 2008-06-05 | 2020-03-10 | National Cancer Center | Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| KR101651661B1 (ko) | 2008-06-30 | 2016-08-26 | 얀센 바이오테크 인코포레이티드 | 만능 줄기 세포의 분화 |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| BRPI0914007A2 (pt) | 2008-07-08 | 2015-11-17 | Oncomed Pharm Inc | anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CA2742268C (en) | 2008-10-31 | 2020-02-18 | Centocor Ortho Biotech Inc. | Differentiation of human embryonic stem cells to the pancreatic endocrine lineage |
| ES2584053T3 (es) | 2008-11-20 | 2016-09-23 | Janssen Biotech, Inc. | Métodos y composiciones para la unión de células y cultivo en sustratos planos |
| KR101837080B1 (ko) | 2008-11-20 | 2018-03-09 | 얀센 바이오테크 인코포레이티드 | 마이크로-캐리어 상의 만능 줄기 세포 배양 |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| US10618964B2 (en) | 2009-04-10 | 2020-04-14 | Ablynx N.V. | Nanobody against IL-6R |
| SG174862A1 (en) | 2009-04-10 | 2011-11-28 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder |
| CA2760332A1 (en) * | 2009-05-01 | 2010-11-04 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| WO2010131733A1 (ja) | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
| JP6219568B2 (ja) | 2009-07-20 | 2017-10-25 | ヤンセン バイオテツク，インコーポレーテツド | ヒト胚性幹細胞の分化 |
| EP2460538B1 (en) * | 2009-07-31 | 2017-09-13 | Shin Maeda | Cancer metastasis inhibitor |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| TW201118166A (en) | 2009-09-24 | 2011-06-01 | Chugai Pharmaceutical Co Ltd | HLA class I-recognizing antibodies |
| TW201119676A (en) * | 2009-10-15 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| KR102071834B1 (ko) * | 2009-10-26 | 2020-01-30 | 에프. 호프만-라 로슈 아게 | 글리코실화된 면역글로불린의 제조 방법 |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2504031A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | ANTI-IL-6 ANTIBODIES AND THEIR USE |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| DK2519542T3 (en) | 2009-12-28 | 2019-01-14 | Onco Therapy Science Inc | ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF. |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| ES2561102T3 (es) * | 2010-01-13 | 2016-02-24 | Oncomed Pharmaceuticals, Inc. | Agentes de unión a Notch1 y procedimientos de uso de los mismos |
| TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
| CN107189979B (zh) | 2010-03-01 | 2021-05-04 | 詹森生物科技公司 | 纯化衍生自多能干细胞的细胞的方法 |
| JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| WO2011108638A1 (ja) | 2010-03-04 | 2011-09-09 | 大日本住友製薬株式会社 | 炎症性腸疾患用薬剤 |
| EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
| WO2011128096A1 (en) | 2010-04-16 | 2011-10-20 | Roche Diagnostics Gmbh | Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
| AU2011250912A1 (en) | 2010-05-12 | 2012-11-22 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| PL2578231T3 (pl) | 2010-05-28 | 2023-01-16 | Chugai Seiyaku Kabushiki Kaisha | Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t |
| EP2578233B1 (en) | 2010-05-28 | 2017-04-26 | National Cancer Center | Therapeutic agent for pancreatic cancer |
| EP2578232A4 (en) | 2010-06-02 | 2013-11-20 | Dainippon Sumitomo Pharma Co | TREATMENT FOR AUTOIMMUN DISEASES AND ALLERGIC DISEASES |
| CA2801107A1 (en) | 2010-06-07 | 2011-12-15 | F. Hoffman-La Roche Ag | Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
| JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP6168991B2 (ja) | 2010-08-31 | 2017-07-26 | ヤンセン バイオテツク，インコーポレーテツド | ヒト胚性幹細胞の分化 |
| PL3590949T3 (pl) | 2010-10-01 | 2022-08-29 | Modernatx, Inc. | Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania |
| JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン， インコーポレイテッド | 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体 |
| US8790649B2 (en) * | 2010-10-29 | 2014-07-29 | Immunogen, Inc. | EGFR-binding molecules and immunoconjugates thereof |
| EP2638067A2 (en) | 2010-11-08 | 2013-09-18 | Genentech, Inc. | Subcutaneously administered anti-il-6 receptor antibody |
| EP3318633A1 (en) | 2010-11-17 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| ES2847891T3 (es) | 2010-11-23 | 2021-08-04 | Vitaeris Inc | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral |
| US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| WO2012101253A1 (en) | 2011-01-28 | 2012-08-02 | Sanofi | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| BR112013021526B1 (pt) | 2011-02-25 | 2021-09-21 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio |
| MX2013010011A (es) | 2011-03-01 | 2014-10-24 | Amgen Inc | Agentes de unión biespecífica. |
| SG193610A1 (en) | 2011-03-25 | 2013-11-29 | Amgen Inc | Anti - sclerostin antibody crystals and formulations thereof |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| DK3006464T3 (en) | 2011-06-10 | 2018-09-17 | Canada Minister Nat Defence | ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF |
| ES2746052T3 (es) | 2011-06-28 | 2020-03-04 | Inhibrx Lp | Polipéptidos de fusión de serpina y métodos de uso de los mismos |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| EP2735315B1 (en) | 2011-07-19 | 2019-10-02 | Chugai Seiyaku Kabushiki Kaisha | Stable protein-containing preparation containing argininamide or valinamide |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| WO2013017656A1 (en) | 2011-08-02 | 2013-02-07 | Medizinische Universität Wien | Antagonists of ribonucleases for treating obesity |
| PT2739311T (pt) | 2011-08-04 | 2018-03-26 | Amgen Inc | Método para tratamento de defeitos de lacunas ósseas |
| WO2013017691A1 (en) | 2011-08-04 | 2013-02-07 | Medizinische Universität Innsbruck | Cahgt1p inhibitors for use in the treatment of candidiasis |
| US9630988B2 (en) | 2011-09-01 | 2017-04-25 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2013041722A1 (en) | 2011-09-23 | 2013-03-28 | Ablynx Nv | Prolonged inhibition of interleukin-6 mediated signaling |
| DE102011083811A1 (de) * | 2011-09-30 | 2013-04-04 | Airbus Operations Gmbh | Sitzvorrichtung für ein Luft- oder Raumfahrzeug |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| WO2013059548A1 (en) | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
| EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| JO3370B1 (ar) | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| RU2014121820A (ru) | 2011-11-21 | 2015-12-27 | Иммьюноджен, Инк. | Способ лечения опухолей, устойчивых к анти-egfr терапиям, с помощью конъюгата антитела egfr с цитотоксическим средством |
| AU2011382454B2 (en) | 2011-11-30 | 2017-02-23 | Abbvie Biotechnology Ltd | Vectors and host cells comprising a modified SV40 promoter for protein expression |
| EP3272364B1 (en) * | 2011-12-13 | 2020-07-29 | Nordic Nanovector ASA | Chimeric therapeutic anti-cd37 antibodie hh1 |
| PT2791160T (pt) | 2011-12-16 | 2022-07-04 | Modernatx Inc | Composições arnm modificado |
| WO2013095953A1 (en) | 2011-12-22 | 2013-06-27 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into single hormonal insulin positive cells |
| CN104039828B (zh) | 2011-12-28 | 2017-07-21 | 安进公司 | 通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法 |
| BR112014015851A2 (pt) | 2011-12-30 | 2019-09-24 | Abbvie Inc | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 |
| PE20142242A1 (es) | 2012-03-15 | 2015-01-08 | Janssen Biotech Inc | Anticuerpos humanos anti-cd27, metodos, y usos |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| AU2013243955B2 (en) | 2012-04-02 | 2018-02-22 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| BR112014025693B1 (pt) | 2012-04-17 | 2021-12-07 | F. Hoffmann-La Roche Ag | Método de produção recombinante de um polipeptídeo em uma célula bacteriana |
| KR101510830B1 (ko) | 2012-05-11 | 2015-04-10 | 가톨릭대학교 산학협력단 | 생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법 |
| KR101510831B1 (ko) * | 2012-05-11 | 2015-04-10 | 가톨릭대학교 산학협력단 | 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제 |
| KR101510302B1 (ko) * | 2012-05-11 | 2015-04-10 | 가톨릭대학교 산학협력단 | Ｉｌ-６ 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제 |
| EP2859091B1 (en) | 2012-06-08 | 2018-08-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
| EP3626267A1 (en) | 2012-07-05 | 2020-03-25 | UCB Pharma, S.A. | Treatment for bone diseases |
| CN104797132B (zh) | 2012-09-13 | 2017-06-30 | 中外制药株式会社 | 基因敲入非人动物 |
| WO2014052462A2 (en) | 2012-09-25 | 2014-04-03 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| EP4039798A1 (en) | 2012-12-31 | 2022-08-10 | Janssen Biotech, Inc. | Suspension and clustering of human pluripotent cells |
| JP6557147B2 (ja) | 2012-12-31 | 2019-08-07 | ヤンセン バイオテツク，インコーポレーテツド | Ｈｂ９調節物を用いたヒト胚性幹細胞の膵臓内分泌細胞への分化 |
| US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
| WO2014105543A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| EP2970459A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
| DK3677591T5 (da) | 2013-04-29 | 2024-08-26 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antistoffer og fusioner til svækket interferon alpha-2b |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| US10782290B2 (en) | 2013-06-11 | 2020-09-22 | National Center Of Neurology And Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy |
| RU2674996C2 (ru) | 2013-07-04 | 2018-12-14 | Ф. Хоффманн-Ля Рош Аг | Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки |
| WO2015046467A1 (ja) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| EP4223874A3 (en) | 2013-12-26 | 2023-09-27 | Mitsubishi Tanabe Pharma Corporation | Human anti-il-33 neutralizing monoclonal antibody |
| MY181081A (en) | 2013-12-27 | 2020-12-17 | Chugai Pharmaceutical Co Ltd | Method for purifying antibody having low isoelectric point |
| EP2898896A1 (en) | 2014-01-22 | 2015-07-29 | Université Pierre et Marie Curie (Paris 6) | Agents for use in the treatment of retinal inflammation |
| WO2015116852A1 (en) | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| CA2942101A1 (en) | 2014-03-21 | 2015-09-24 | Abbvie Inc. | Anti-egfr antibodies and antibody drug conjugates |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| RU2694311C2 (ru) | 2014-05-16 | 2019-07-11 | Янссен Байотек, Инк. | Применение малых молекул для увеличения экспрессии mafa в панкреатических эндокринных клетках |
| EP3185004A4 (en) | 2014-08-20 | 2018-05-30 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| AU2015334984A1 (en) | 2014-10-21 | 2017-04-13 | Ablynx Nv | Treatment of IL-6R related diseases |
| EA037749B1 (ru) | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| US11384350B2 (en) | 2014-12-15 | 2022-07-12 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing |
| EP3240805B1 (en) | 2014-12-15 | 2024-11-27 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| RS62749B1 (sr) | 2014-12-19 | 2022-01-31 | Chugai Pharmaceutical Co Ltd | Anti-c5 antitela i načini njihove upotrebe |
| CA2974547A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof |
| JP6130983B2 (ja) | 2015-02-27 | 2017-05-17 | 中外製薬株式会社 | Ｉｌ−６関連疾患治療用組成物 |
| AR104050A1 (es) | 2015-03-26 | 2017-06-21 | Chugai Pharmaceutical Co Ltd | Proceso de producción con iones de cobre controlados |
| US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
| EP3299810B1 (en) | 2015-05-19 | 2021-07-07 | National Center of Neurology and Psychiatry | Method for determining application of novel therapy to multiple sclerosis (ms) patient |
| JP7128460B2 (ja) | 2015-06-04 | 2022-08-31 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| CN107922507B (zh) | 2015-08-18 | 2022-04-05 | 瑞泽恩制药公司 | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 |
| US10968278B2 (en) | 2015-11-03 | 2021-04-06 | Sanofi Biotechnology | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION |
| US11484591B2 (en) | 2016-02-22 | 2022-11-01 | Ohio State Innovation Foundation | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| TW201735947A (zh) | 2016-03-14 | 2017-10-16 | Chugai Pharmaceutical Co Ltd | 用於癌之治療的細胞傷害誘導治療劑 |
| MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
| MA44780A (fr) | 2016-04-28 | 2019-03-06 | Chugai Pharmaceutical Co Ltd | Préparation contenant un anticorps |
| IL264626B (en) | 2016-08-05 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Composition for prophylaxis or treatment of il-8 related diseases |
| EP3506943B1 (en) | 2016-09-02 | 2025-01-29 | The Regents of The University of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| BR112019005328A2 (pt) | 2016-09-27 | 2019-06-18 | Fresenius Kabi Deutschland Gmbh | composição farmacêutica líquida |
| KR102051177B1 (ko) * | 2016-10-19 | 2019-12-17 | 주식회사 엘지화학 | 전압 분배를 이용한 스위치 진단 장치 및 방법 |
| CN110062620B (zh) | 2016-10-31 | 2023-12-05 | 德国费森尤斯卡比有限公司 | 液体药物组合物 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| EP3596175A4 (en) | 2017-03-17 | 2021-01-13 | The Ohio State Innovation Foundation | NANOPARTICLES FOR THE ADMINISTRATION OF CHEMOPREVENTIVE AGENTS |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| CN107098969B (zh) * | 2017-06-28 | 2018-10-12 | 武汉波睿达生物科技有限公司 | 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用 |
| MY199245A (en) | 2017-08-31 | 2023-10-23 | Hyogo College Medicine | Il-33 antagonist-containing therapeutic agent for endometriosis |
| AU2018331725A1 (en) | 2017-09-13 | 2020-04-23 | Jiangsu Hengrui Medicine Co., Ltd. | IL-6R antibody and antigen binding fragment thereof and medical use |
| WO2019078344A1 (ja) | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| IL274265B1 (en) | 2017-11-01 | 2025-09-01 | Chugai Pharmaceutical Co Ltd | Variant and isoform of an antibody with attenuated biological activity |
| EP3747469A4 (en) | 2018-01-31 | 2022-03-23 | Motokazu Kato | THERAPEUTIC FOR ASTHMA WITH IL-6 INHIBITOR |
| TWI827585B (zh) | 2018-03-15 | 2024-01-01 | 日商中外製藥股份有限公司 | 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法 |
| IL316596A (en) | 2018-03-30 | 2024-12-01 | Amgen Inc | C-terminal antibody variants |
| TWI840360B (zh) | 2018-05-21 | 2024-05-01 | 日商中外製藥股份有限公司 | 密封於玻璃容器之凍結乾燥的製劑、套組、製造凍結乾燥製劑的方法、防止或減低凍結乾燥製劑的玻璃容器成霧的方法、及容器內面經過硫酸銨處理或ｖｉｓｔ處理之玻璃容器 |
| WO2019230725A1 (ja) | 2018-05-28 | 2019-12-05 | 中外製薬株式会社 | 充填ノズル |
| US11319375B2 (en) | 2018-08-29 | 2022-05-03 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for treating subjects having rheumatoid arthritis |
| CA3127669A1 (en) * | 2019-01-07 | 2020-07-16 | Hunan Siweikang Therapeutics Co. Ltd | Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy |
| CA3128212A1 (en) | 2019-01-31 | 2020-08-06 | Sanofi Biotechnology | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
| JPWO2020202839A1 (member.php) | 2019-03-29 | 2020-10-08 | ||
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020209318A1 (ja) | 2019-04-10 | 2020-10-15 | 中外製薬株式会社 | Ｆｃ領域改変抗体の精製方法 |
| CA3135694A1 (en) | 2019-04-17 | 2020-10-22 | Hiroshima University | Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination |
| BR112021021077A2 (pt) | 2019-04-24 | 2021-12-14 | E Zilberstein Moshe | Métodos de diagnóstico e tratamento de artrite reumatoide |
| EP3976644A4 (en) | 2019-05-31 | 2022-12-14 | The Johns Hopkins University | BI-SPECIFIC LIAISONS |
| KR20230061198A (ko) | 2019-06-04 | 2023-05-08 | 사노피 바이오테크놀로지 | 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법 |
| CN114375205A (zh) | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| CN110483640B (zh) * | 2019-07-16 | 2020-05-01 | 北京汇智和源生物技术有限公司 | 白介素-6r的人源化单克隆抗体、其编码基因及应用 |
| US20240254136A1 (en) | 2020-03-03 | 2024-08-01 | Redona Therapeutics, Inc. | Compounds targeting rna-binding proteins or rna-modifying proteins |
| EP4107184A1 (en) | 2020-03-23 | 2022-12-28 | Genentech, Inc. | Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist |
| US20230174656A1 (en) | 2020-03-23 | 2023-06-08 | Genentech, Inc. | Tocilizumab and remdesivir combination therapy for covid-19 pneumonia |
| CN115867577A (zh) | 2020-03-23 | 2023-03-28 | 基因泰克公司 | 用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物 |
| WO2021228917A1 (en) | 2020-05-15 | 2021-11-18 | F. Hoffmann-La Roche Ag | Prevention of visible particle formation in parenteral protein solutions |
| US20230167182A1 (en) * | 2020-05-18 | 2023-06-01 | Biosion Inc. | Antibodies binding il6r and uses thereof |
| KR20220028972A (ko) | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
| JP2023541921A (ja) | 2020-09-17 | 2023-10-04 | ジェネンテック， インコーポレイテッド | Ｃｏｖｉｄ－１９肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験（ｅｍｐａｃｔａ）の結果 |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| WO2022191306A1 (ja) | 2021-03-12 | 2022-09-15 | 中外製薬株式会社 | 重症筋無力症の治療または予防用の医薬組成物 |
| WO2022261417A1 (en) | 2021-06-11 | 2022-12-15 | Genentech, Inc. | Method for treating chronic obstructive pulmonary disease with an st2 antagonist |
| US20240404622A1 (en) | 2021-10-08 | 2024-12-05 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing prefilled syringe formulation |
| AU2023262861A1 (en) | 2022-04-26 | 2024-11-07 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical-preparation-containing syringe equipped with filter |
| WO2024107752A2 (en) | 2022-11-15 | 2024-05-23 | Onestone Therapeutics Llc | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| TW202444922A (zh) | 2023-03-31 | 2024-11-16 | 國立大學法人大阪大學 | 用於預測敗血症患者之預後的生物標記及其用途 |
| CN121038814A (zh) | 2023-04-14 | 2025-11-28 | 中外制药株式会社 | 用于稳定含蛋白质药物制剂的方法 |
| WO2025198912A1 (en) | 2024-03-21 | 2025-09-25 | Hoffmann-La Roche Inc. | Methods of treating myasthenia gravis |
| HUP2400216A1 (hu) | 2024-04-17 | 2025-10-28 | Richter Gedeon Nyrt | N-terminális glutamint tartalmazó immunglobulinok tisztítására szolgáló eljárások |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2409607A1 (de) | 2010-07-20 | 2012-01-25 | Josef Kurz | Schuhlöffel |
| EP2413908A1 (fr) | 2009-03-31 | 2012-02-08 | Ethypharm | Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des "limus" |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4304583A (en) * | 1980-06-02 | 1981-12-08 | Corning Glass Works | Process for drying optical waveguide preforms |
| JPS6147500A (ja) * | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5082782A (en) | 1988-12-27 | 1992-01-21 | Worcester Polytechnic Institute | Production of horseshoe crab amebocytes in vitro |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5216128A (en) * | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| CA2021594C (en) * | 1989-07-20 | 2002-01-08 | Tadamitsu Kishimoto | Antibody to human interleukin-6 receptor |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
-
1992
- 1992-04-24 JP JP50889892A patent/JP3370324B2/ja not_active Expired - Lifetime
- 1992-04-24 KR KR1019930703229A patent/KR100249937B1/ko not_active Expired - Lifetime
- 1992-04-24 DK DK92909376T patent/DK0628639T3/da active
- 1992-04-24 US US08/137,117 patent/US5795965A/en not_active Expired - Lifetime
- 1992-04-24 HU HU9303002A patent/HU218140B/hu active Protection Beyond IP Right Term
- 1992-04-24 ES ES92909376T patent/ES2134212T3/es not_active Expired - Lifetime
- 1992-04-24 DE DE69229482T patent/DE69229482T2/de not_active Expired - Lifetime
- 1992-04-24 WO PCT/JP1992/000544 patent/WO1992019759A1/ja not_active Ceased
- 1992-04-24 AT AT92909376T patent/ATE181575T1/de active
- 1992-04-24 RU RU93055358A patent/RU2139351C1/ru active Protection Beyond IP Right Term
- 1992-04-24 DE DE122009000019C patent/DE122009000019I1/de active Pending
- 1992-04-24 TW TW081103237A patent/TW205553B/zh active
- 1992-04-24 AU AU16740/92A patent/AU668349B2/en not_active Expired
- 1992-04-24 EP EP92909376A patent/EP0628639B1/en not_active Expired - Lifetime
-
1995
- 1995-05-08 US US08/436,717 patent/US5817790A/en not_active Expired - Lifetime
-
1996
- 1996-06-26 AU AU56213/96A patent/AU692100B2/en not_active Expired
-
1999
- 1999-09-08 GR GR990402267T patent/GR3031174T3/el unknown
- 1999-11-29 JP JP33828699A patent/JP3176598B2/ja not_active Expired - Lifetime
-
2000
- 2000-07-28 JP JP2000229748A patent/JP3913965B2/ja not_active Expired - Lifetime
-
2003
- 2003-10-06 JP JP2003347675A patent/JP3616087B2/ja not_active Expired - Lifetime
-
2004
- 2004-05-04 US US10/837,904 patent/US7479543B2/en not_active Expired - Fee Related
-
2006
- 2006-12-15 JP JP2006338832A patent/JP2007082560A/ja not_active Withdrawn
-
2007
- 2007-09-28 JP JP2007255248A patent/JP2008073049A/ja active Pending
-
2009
- 2009-04-02 NL NL300383C patent/NL300383I2/nl unknown
- 2009-04-24 LU LU91556C patent/LU91556I2/fr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2413908A1 (fr) | 2009-03-31 | 2012-02-08 | Ethypharm | Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des "limus" |
| EP2409607A1 (de) | 2010-07-20 | 2012-01-25 | Josef Kurz | Schuhlöffel |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021211006A1 (en) | 2020-04-13 | 2021-10-21 | Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency | Inhaled hexapeptide for treating interleukin-6 related respiratory diseases |
| WO2022005321A1 (en) | 2020-06-29 | 2022-01-06 | Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency | Inhaled tocilizumab for treating interleukin-6 related respiratory diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3370324B2 (ja) | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 | |
| JP7469432B2 (ja) | 抗ｇｐｒｃ５ｄ抗体、ｇｐｒｃ５ｄとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 | |
| CN114828965B (zh) | 与hla-a2/mage-a4结合的抗体 | |
| AU763491B2 (en) | Antibodies to CD23, derivatives thereof, and their therapeutic uses | |
| JP3081641B2 (ja) | 抗体の調製 | |
| CN101687035B (zh) | 新化合物 | |
| JPWO1992019759A1 (ja) | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 | |
| USRE46877E1 (en) | Altered antibodies and their preparation | |
| CN114364700A (zh) | 与nkg2d结合的抗体 | |
| WO2019169314A1 (en) | IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE | |
| WO1994028159A1 (en) | Reconstructed human antibody against human interleukin-6 | |
| JPH11507535A (ja) | 腫瘍の成長を抑制する抗体および抗体フラグメント類 | |
| JPH08507680A (ja) | 組換え抗ｖｌａ４抗体分子 | |
| CA2266341A1 (en) | Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin | |
| JP3614183B2 (ja) | ヒトインターロイキン−６に対する再構成ヒト抗体 | |
| JPH05227970A (ja) | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 | |
| JP2022535061A (ja) | 二重特異性結合構築物 | |
| CN115551538A (zh) | 干扰IL-1β受体信号转导的药剂 | |
| WO2024061158A1 (en) | Slit2 related compositions and methods | |
| AU2024287056A1 (en) | Anti-npr1 antibody and pharmaceutical use thereof | |
| JP2024534824A (ja) | 操作された抗ｈｅｒ２二重特異性タンパク質 | |
| HK40091593A (zh) | 与cd3和folr1结合的抗体 | |
| HK40033147B (zh) | 抗tigit的抗体、其制备方法和应用 | |
| HK40076302B (zh) | 新型多肽复合物 | |
| HK40064430A (en) | Antibodies binding to nkg2d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141115 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141115 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141115 Year of fee payment: 12 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141115 Year of fee payment: 12 |
|
| R153 | Grant of patent term extension |
Free format text: JAPANESE INTERMEDIATE CODE: R153 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20171115 Year of fee payment: 15 |
|
| EXPY | Cancellation because of completion of term |